On September 30, 2026, CalciMedica, Inc. filed a prospectus supplement with the Securities and Exchange Commission (SEC) to update its at-the-market (ATM) stock offering program. The filing indicates the company intends to offer and sell shares of its common stock having an aggregate offering price of up to $25,000,000. The offering will be conducted under an existing agreement with H.C. Wainwright & Co., dated August 11, 2023.
The shares are to be sold from time to time pursuant to the company’s shelf registration statement on Form S-3 (Registration No. 333-293972). This registration statement was initially filed with the SEC on March 3, 2026, and was declared effective on March 11, 2026. The prospectus supplement was filed under this existing registration framework.
Attached to the filing as Exhibit 5.1 is a legal opinion from Cooley LLP regarding the legality of the shares of common stock that may be issued under the offering agreement and covered by the prospectus supplement. The company’s principal executive offices are located at 505 Coast Boulevard South, Suite 300-9, La Jolla, California 92037.
